多西他赛+表阿霉素方案在乳腺癌新辅助化疗中的应用

目的探讨多西他赛+表阿霉素(DE)方案在乳腺癌新辅助化疗中的作用及其临床意义。方法术前均按DE方案进行新辅助化疗,即注射用多西他赛75mg/m2,表阿霉素75mg/m2,第1天,静脉滴注。每21d为1个周期,共进行2～3个周期的治疗。治疗后分别进行疗效评价。结果 48例中有2例获得临床完全缓解(cCR),35例获得临床部分缓解(cPR),11例疾病稳定(SD),无临床进展(PD)病例,有效率为77%(37/48);48例均不具备保乳手术条件的患者中,有19例(40%)经新辅助化疗后肿瘤缩小,病期降低,符合保乳手术条件。结论使用DE方案对局部进展期乳腺癌进行3周期新辅助化疗,可以获得良好的肿瘤缩小效果,并可降低临床分期、提高肿瘤切除率。

Effect and adverse effect of DE for primary systemic chemotherapy in breast cancer

Objective To explore the effectiveness and clinical significance of DE program in neoadjuvant chemotherapy for local progression breast cancer.Methods All forty-eight patients were receiving neoadjuvant chemotherapy before surgery.The program was docetaxel 75 mg/m2,Epirubicin 75 mg/m2.A course of treatment was 21 days.Evaluation was made after two to three courses of treatment.Results Two case was cCR(clinical completely remission) of all the 48 cases,35 cases were cPR(clinical partial remission),11 cases were SD(stabilization of disease),no case was PD(progression of disease),and the effective power was 77%(37/48).Eighteen cases were cPR among the 26 cases which two courses of neoadjuvant chemotherapy were taken.Two case was cCR and 17 cases were cPR among the other 22 cases in which three courses were taken.Conclusion For patients with local progression breast cancer,after three courses of neoadjuvant chemotherapy,the diminution of tumor volume was obvious,the clinical stage was stepped down,and the resection ratio was raised.